GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Interest Coverage

FENC (Fennec Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Fennec Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $-5.22 Mil. Fennec Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $-1.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Fennec Pharmaceuticals's Interest Coverage or its related term are showing as below:

FENC' s Interest Coverage Range Over the Past 10 Years
Min: 0.38   Med: No Debt   Max: No Debt
Current: 0.38


FENC's Interest Coverage is ranked worse than
98.51% of 335 companies
in the Biotechnology industry
Industry Median: 137.08 vs FENC: 0.38

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Fennec Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Fennec Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Fennec Pharmaceuticals Interest Coverage Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 13.27 - -

Competitive Comparison of Fennec Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Fennec Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Interest Coverage falls into.



Fennec Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fennec Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Fennec Pharmaceuticals's Interest Expense was $-3.39 Mil. Its Operating Income was $-13.06 Mil. And its Long-Term Debt & Capital Lease Obligation was $30.93 Mil.

Fennec Pharmaceuticals did not have earnings to cover the interest expense.

Fennec Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Fennec Pharmaceuticals's Interest Expense was $-1.03 Mil. Its Operating Income was $-5.22 Mil. And its Long-Term Debt & Capital Lease Obligation was $32.10 Mil.

Fennec Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Fennec Pharmaceuticals  (NAS:FENC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Fennec Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040